SARS-CoV-2 infects human cardiomyocytes promoted by inflammation and oxidative stress

2022 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​SARS-CoV-2 infects human cardiomyocytes promoted by inflammation and oxidative stress​
Tangos, M.; Budde, H.; Kolijn, D.; Sieme, M.; Zhazykbayeva, S.; Lódi, M. & Herwig, M. et al.​ (2022) 
International Journal of Cardiology362 pp. 196​-205​.​ DOI: https://doi.org/10.1016/j.ijcard.2022.05.055 

Documents & Media

License

Published Version

Usage license

Details

Authors
Tangos, Melina; Budde, Heidi; Kolijn, Detmar; Sieme, Marcel; Zhazykbayeva, Saltanat; Lódi, Mária; Herwig, Melissa; Gömöri, Kamilla; Hassoun, Roua; Robinson, Emma Louise; Hamdani, Nazha
Abstract
Introduction The respiratory illness triggered by severe acute respiratory syndrome virus-2 (SARS-CoV-2) is often particularly serious or fatal amongst patients with pre-existing heart conditions. Although the mechanisms underlying SARS-CoV-2-related cardiac damage remain elusive, inflammation (i.e. ‘cytokine storm’) and oxidative stress are likely involved. Methods and results Here we sought to determine: 1) if cardiomyocytes are targeted by SARS-CoV-2 and 2) how inflammation and oxidative stress promote the viral entry into cardiac cells. We analysed pro-inflammatory and oxidative stress and its impact on virus entry and virus-associated cardiac damage from SARS-CoV-2 infected patients and compared it to left ventricular myocardial tissues obtained from non-infected transplanted hearts either from end stage heart failure or non-failing hearts (donor group). We found that neuropilin-1 potentiates SARS-CoV-2 entry into human cardiomyocytes, a phenomenon driven by inflammatory and oxidant signals. These changes accounted for increased proteases activity and apoptotic markers thus leading to cell damage and apoptosis. Conclusion This study provides new insights into the mechanisms of SARS-CoV-2 entry into the heart and defines promising targets for antiviral interventions for COVID-19 patients with pre-existing heart conditions or patients with co-morbidities.
Issue Date
2022
Journal
International Journal of Cardiology 
Organization
Klinik für Kardiologie und Pneumologie ; Deutsches Zentrum für Herz-Kreislauf-Forschung e.V. ; Universitätsmedizin Göttingen 
ISSN
0167-5273
Language
English

Reference

Citations


Social Media